Health ❯ Medicine

Pharmaceuticals

Weight Loss Drug Development Clinical Trials Weight Loss Drugs Diabetes Acetaminophen Drug Approval Pain Relief Drug Safety Cannabis Over-the-Counter Medications Antibiotics Abortion Side Effects Pregnancy Obesity Obesity Treatments Cancer Treatment GLP-1 Drugs Weight Loss Medications Peptides Paracetamol Weight-loss Drugs Pain Management Pain Relievers Obesity Treatment Insulin Weight-Loss Drugs Biotechnology Diabetes Treatment Erectile Dysfunction Aspirin Weight Management Vaccines Prescription Drugs Drug Pricing Abortion Pill Semaglutide Drug Side Effects Supplements Contraceptives Autism Veterinary Medicine Obesity Drugs Abortion Drugs Drug Trials Antiviral Drugs Oncology Neurology Diabetes Medication Recalls FDA Approval Dietary Supplements Alzheimer's Disease Biopharma Counterfeit Drugs Over-the-Counter Drugs Cancer Doping Substances Diabetes Medications Drug Discovery Opioids Inhalers HIV/AIDS Medication Drug Regulation Drug Use Weight-loss drugs Adverse Effects Safety Eye Care Allergy Treatment Birth Control Therapies FDA Regulations Abortion-Inducing Drugs Product Safety HIV Prevention Painkillers Drug Formulation Contamination Contraception Mifepristone Regulations Vaccine Development Medication Abortion Hormone Therapy Asthma Cosmetic Procedures Medication Safety Generic Medicines Supply Chain mRNA Therapy Medications Injectable Medications Cardiovascular Health Weight-loss Treatments Injectable Diabetes Medications Heartburn Drugs GLP-1 Class

South Korea Plans Phased Rollout of Abortion Pills by Q1 2027

Officials say limiting prescriptions to doctors for an initial two years is meant to curb unsafe online purchases.

AI-Designed Drug Rentosertib Lowers Biological-Age Signals in Small Trial

Novo Nordisk’s Semaglutide Eases Childhood Obesity as Heart-Drug Trials Are Halted

Alumis Shares Plunge After Phase 2b Lupus Trial Misses Primary Goal

Enveda’s ENV-308 Clears Phase 1 Safety Test

Eli Lilly Opens Limited Early Access to Experimental Obesity Drug Retatrutide

FDA Advisory Panel Backs Pharmacy Compounding of Six Experimental Peptides

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

Enzyme Platform Produces Promising, Less-Toxic Polyene Candidate Nys34

FDA Staff Flags Major Flaws in Capricor’s Deramiocel Data

FDA Approves First Over-the-Counter Tylenol–Naproxen Combination Pill

FDA Advisers Recommend BPC-157 for Pharmacy Compounding

Lilly Will Seek FDA Approval for Retatrutide in Q1 2027 After Two More Positive Phase 3 Trials

Lakewood-Amedex Says Nu-3 Did Not Induce Resistance in Lab Tests as Stock Soars

Generics and Pills Expand Access to GLP‑1s, but Uptake and Coverage Remain Uneven

Lawmakers Demand Answers After Single Patient Received Experimental Eli Lilly Obesity Drug

EMA Committee Recommends Revoking Tavneos Authorization

One 79-Year-Old Granted Compassionate‑Use Access to Eli Lilly’s Unapproved Obesity Drug

Daraxonrasib Doubles Survival in Phase 3 Trial of Treated Metastatic Pancreatic Cancer

FDA Launches Retrospective Safety Study of Mifepristone